Turkey
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.43 (2.31 - 2.56) | 2019 | Modelled | IHME |
| 2.54 (2.41 - 2.67) | 2018 | Modelled | IHME |
| 2.61 (2.47 - 2.76) | 2017 | Modelled | IHME |
| 2.65 (2.52 - 2.78) | 2016 | Modelled | IHME |
| 2.68 (2.54 - 2.82) | 2015 | Modelled | IHME |
| 2.72 (2.59 - 2.86) | 2014 | Modelled | IHME |
| 2.78 (2.65 - 2.92) | 2013 | Modelled | IHME |
| 2.84 (2.71 - 2.99) | 2012 | Modelled | IHME |
| 2.91 (2.76 - 3.07) | 2011 | Modelled | IHME |
| 2.98 (2.82 - 3.15) | 2010 | Modelled | IHME |
| 3.04 (2.89 - 3.21) | 2009 | Modelled | IHME |
| 3.11 (2.96 - 3.28) | 2008 | Modelled | IHME |
| 3.18 (3.03 - 3.35) | 2007 | Modelled | IHME |
| 3.25 (3.09 - 3.43) | 2006 | Modelled | IHME |
| 3.33 (3.16 - 3.52) | 2005 | Modelled | IHME |
| 3.41 (3.24 - 3.59) | 2004 | Modelled | IHME |
| 3.49 (3.32 - 3.68) | 2003 | Modelled | IHME |
| 3.57 (3.39 - 3.77) | 2002 | Modelled | IHME |
| 3.66 (3.46 - 3.88) | 2001 | Modelled | IHME |
| 3.75 (3.53 - 3.99) | 2000 | Modelled | IHME |
| 3.85 (3.61 - 4.09) | 1999 | Modelled | IHME |
| 3.95 (3.71 - 4.19) | 1998 | Modelled | IHME |
| 4.05 (3.80 - 4.29) | 1997 | Modelled | IHME |
| 4.14 (3.88 - 4.40) | 1996 | Modelled | IHME |
| 4.22 (3.95 - 4.50) | 1995 | Modelled | IHME |
| 4.29 (4.02 - 4.57) | 1994 | Modelled | IHME |
| 4.35 (4.09 - 4.62) | 1993 | Modelled | IHME |
| 4.41 (4.16 - 4.68) | 1992 | Modelled | IHME |
| 4.46 (4.19 - 4.74) | 1991 | Modelled | IHME |
| 4.5 (4.22 - 4.79) | 1990 | Modelled | IHME |
| 3 | 2003 | Survey/reported | Ozsoy MF et al, 2003 |
| 2.5 | 2009 | Survey/reported | Akcama FZ et al, 2009 |
| 2.63 (2.08 - 3.28) | 2015 | Modelled | WHO |
Showing out of
Show more
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.17 (0.14 - 0.20) | 2019 | Modelled | IHME |
| 0.18 (0.15 - 0.21) | 2018 | Modelled | IHME |
| 0.19 (0.16 - 0.23) | 2017 | Modelled | IHME |
| 0.2 (0.17 - 0.24) | 2016 | Modelled | IHME |
| 0.21 (0.18 - 0.25) | 2015 | Modelled | IHME |
| 0.22 (0.19 - 0.26) | 2014 | Modelled | IHME |
| 0.24 (0.20 - 0.27) | 2013 | Modelled | IHME |
| 0.25 (0.21 - 0.29) | 2012 | Modelled | IHME |
| 0.27 (0.22 - 0.31) | 2011 | Modelled | IHME |
| 0.29 (0.24 - 0.34) | 2010 | Modelled | IHME |
| 0.33 (0.27 - 0.38) | 2009 | Modelled | IHME |
| 0.38 (0.32 - 0.45) | 2008 | Modelled | IHME |
| 0.45 (0.38 - 0.53) | 2007 | Modelled | IHME |
| 0.53 (0.44 - 0.63) | 2006 | Modelled | IHME |
| 0.62 (0.52 - 0.73) | 2005 | Modelled | IHME |
| 0.73 (0.61 - 0.85) | 2004 | Modelled | IHME |
| 0.85 (0.72 - 1) | 2003 | Modelled | IHME |
| 1 (0.85 - 1.18) | 2002 | Modelled | IHME |
| 1.17 (0.99 - 1.38) | 2001 | Modelled | IHME |
| 1.37 (1.16 - 1.63) | 2000 | Modelled | IHME |
| 1.69 (1.43 - 1.98) | 1999 | Modelled | IHME |
| 2.15 (1.81 - 2.50) | 1998 | Modelled | IHME |
| 2.63 (2.20 - 3.06) | 1997 | Modelled | IHME |
| 3.03 (2.52 - 3.53) | 1996 | Modelled | IHME |
| 3.25 (2.69 - 3.81) | 1995 | Modelled | IHME |
| 3.34 (2.79 - 3.92) | 1994 | Modelled | IHME |
| 3.42 (2.85 - 4) | 1993 | Modelled | IHME |
| 3.47 (2.90 - 4.09) | 1992 | Modelled | IHME |
| 3.51 (2.92 - 4.16) | 1991 | Modelled | IHME |
| 3.52 (2.93 - 4.16) | 1990 | Modelled | IHME |
| 0.32 (0.22 - 0.48) | 2015 | Modelled | WHO |
Showing out of
Show more
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 4.34 (3.25 - 5.68) | 2019 | Modelled | IHME |
| 4.26 (3.26 - 5.53) | 2018 | Modelled | IHME |
| 4.24 (3.31 - 5.40) | 2017 | Modelled | IHME |
| 4.36 (3.51 - 5.40) | 2016 | Modelled | IHME |
| 4.52 (3.72 - 5.47) | 2015 | Modelled | IHME |
| 4.53 (3.77 - 5.41) | 2014 | Modelled | IHME |
| 4.51 (3.77 - 5.39) | 2013 | Modelled | IHME |
| 4.51 (3.76 - 5.34) | 2012 | Modelled | IHME |
| 4.55 (3.80 - 5.39) | 2011 | Modelled | IHME |
| 4.55 (3.76 - 5.40) | 2010 | Modelled | IHME |
| 4.66 (3.87 - 5.56) | 2009 | Modelled | IHME |
| 4.84 (3.96 - 5.84) | 2008 | Modelled | IHME |
| 5.07 (4.10 - 6.20) | 2007 | Modelled | IHME |
| 5.3 (4.29 - 6.49) | 2006 | Modelled | IHME |
| 5.45 (4.45 - 6.66) | 2005 | Modelled | IHME |
| 5.61 (4.59 - 6.83) | 2004 | Modelled | IHME |
| 5.8 (4.80 - 7.05) | 2003 | Modelled | IHME |
| 6.07 (5.14 - 7.21) | 2002 | Modelled | IHME |
| 6 (5.05 - 7.11) | 2001 | Modelled | IHME |
| 6.04 (5.09 - 7.10) | 2000 | Modelled | IHME |
| 6.38 (5.33 - 7.50) | 1999 | Modelled | IHME |
| 6.56 (5.40 - 7.76) | 1998 | Modelled | IHME |
| 6.66 (5.51 - 7.93) | 1997 | Modelled | IHME |
| 6.67 (5.44 - 7.91) | 1996 | Modelled | IHME |
| 6.75 (5.43 - 8.03) | 1995 | Modelled | IHME |
| 6.74 (5.40 - 8.08) | 1994 | Modelled | IHME |
| 6.65 (5.30 - 8) | 1993 | Modelled | IHME |
| 6.57 (5.19 - 7.92) | 1992 | Modelled | IHME |
| 6.5 (5.09 - 7.90) | 1991 | Modelled | IHME |
| 6.39 (4.96 - 7.86) | 1990 | Modelled | IHME |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 3,530 (2,645 - 4,618) | 2019 | Modelled | IHME |
| 3,454 (2,642 - 4,483) | 2018 | Modelled | IHME |
| 3,417 (2,670 - 4,353) | 2017 | Modelled | IHME |
| 3,494 (2,812 - 4,329) | 2016 | Modelled | IHME |
| 3,583 (2,953 - 4,337) | 2015 | Modelled | IHME |
| 3,557 (2,955 - 4,247) | 2014 | Modelled | IHME |
| 3,490 (2,913 - 4,164) | 2013 | Modelled | IHME |
| 3,434 (2,862 - 4,072) | 2012 | Modelled | IHME |
| 3,427 (2,864 - 4,060) | 2011 | Modelled | IHME |
| 3,404 (2,813 - 4,037) | 2010 | Modelled | IHME |
| 3,464 (2,875 - 4,131) | 2009 | Modelled | IHME |
| 3,581 (2,930 - 4,316) | 2008 | Modelled | IHME |
| 3,726 (3,011 - 4,560) | 2007 | Modelled | IHME |
| 3,869 (3,135 - 4,740) | 2006 | Modelled | IHME |
| 3,950 (3,228 - 4,832) | 2005 | Modelled | IHME |
| 4,035 (3,301 - 4,912) | 2004 | Modelled | IHME |
| 4,140 (3,425 - 5,029) | 2003 | Modelled | IHME |
| 4,292 (3,632 - 5,097) | 2002 | Modelled | IHME |
| 4,198 (3,535 - 4,974) | 2001 | Modelled | IHME |
| 4,181 (3,527 - 4,920) | 2000 | Modelled | IHME |
| 4,371 (3,648 - 5,135) | 1999 | Modelled | IHME |
| 4,437 (3,652 - 5,254) | 1998 | Modelled | IHME |
| 4,452 (3,678 - 5,296) | 1997 | Modelled | IHME |
| 4,395 (3,588 - 5,210) | 1996 | Modelled | IHME |
| 4,382 (3,525 - 5,215) | 1995 | Modelled | IHME |
| 4,311 (3,453 - 5,171) | 1994 | Modelled | IHME |
| 4,193 (3,342 - 5,038) | 1993 | Modelled | IHME |
| 4,073 (3,215 - 4,912) | 1992 | Modelled | IHME |
| 3,957 (3,101 - 4,811) | 1991 | Modelled | IHME |
| 3,819 (2,966 - 4,696) | 1990 | Modelled | IHME |
| 4,200 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 42 (34 - 51) | 2019 | Modelled | IHME |
| 42 (34 - 51) | 2018 | Modelled | IHME |
| 42 (34 - 51) | 2017 | Modelled | IHME |
| 42 (35 - 51) | 2016 | Modelled | IHME |
| 43 (35 - 51) | 2015 | Modelled | IHME |
| 43 (35 - 51) | 2014 | Modelled | IHME |
| 43 (35 - 51) | 2013 | Modelled | IHME |
| 44 (36 - 52) | 2012 | Modelled | IHME |
| 44 (36 - 53) | 2011 | Modelled | IHME |
| 45 (37 - 54) | 2010 | Modelled | IHME |
| 45 (37 - 54) | 2009 | Modelled | IHME |
| 46 (38 - 54) | 2008 | Modelled | IHME |
| 47 (39 - 56) | 2007 | Modelled | IHME |
| 48 (40 - 57) | 2006 | Modelled | IHME |
| 49 (41 - 58) | 2005 | Modelled | IHME |
| 49 (41 - 58) | 2004 | Modelled | IHME |
| 49 (41 - 57) | 2003 | Modelled | IHME |
| 48 (40 - 57) | 2002 | Modelled | IHME |
| 48 (40 - 57) | 2001 | Modelled | IHME |
| 48 (40 - 57) | 2000 | Modelled | IHME |
| 48 (40 - 57) | 1999 | Modelled | IHME |
| 49 (40 - 57) | 1998 | Modelled | IHME |
| 49 (40 - 58) | 1997 | Modelled | IHME |
| 49 (40 - 58) | 1996 | Modelled | IHME |
| 49 (40 - 58) | 1995 | Modelled | IHME |
| 49 (40 - 58) | 1994 | Modelled | IHME |
| 49 (41 - 58) | 1993 | Modelled | IHME |
| 49 (40 - 58) | 1992 | Modelled | IHME |
| 49 (40 - 58) | 1991 | Modelled | IHME |
| 49 (40 - 58) | 1990 | Modelled | IHME |
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 99 | 2018 | Survey/reported | WHO/UNICEF |
| 99 | 2017 | Survey/reported | WHO/UNICEF |
| 99 | 2016 | Survey/reported | WHO/UNICEF |
| 99 | 2015 | Survey/reported | WHO/UNICEF |
| 99 | 2014 | Survey/reported | WHO/UNICEF |
| 99 | 2013 | Survey/reported | WHO/UNICEF |
| 97 | 2012 | Survey/reported | WHO/UNICEF |
| 97 | 2011 | Survey/reported | WHO/UNICEF |
| 97 | 2010 | Survey/reported | WHO/UNICEF |
| 96 | 2009 | Survey/reported | WHO/UNICEF |
| 96 | 2008 | Survey/reported | WHO/UNICEF |
| 96 | 2007 | Survey/reported | WHO/UNICEF |
| 95 | 2006 | Survey/reported | WHO/UNICEF |
| 94 | 2005 | Survey/reported | WHO/UNICEF |
| 88 | 2004 | Survey/reported | WHO/UNICEF |
| 78 | 2003 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 98 | 2018 | Survey/reported | WHO/UNICEF |
| 96 | 2017 | Survey/reported | WHO/UNICEF |
| 98 | 2016 | Survey/reported | WHO/UNICEF |
| 97 | 2015 | Survey/reported | WHO/UNICEF |
| 96 | 2014 | Survey/reported | WHO/UNICEF |
| 97 | 2013 | Survey/reported | WHO/UNICEF |
| 97 | 2012 | Survey/reported | WHO/UNICEF |
| 96 | 2011 | Survey/reported | WHO/UNICEF |
| 96 | 2010 | Survey/reported | WHO/UNICEF |
| 94 | 2009 | Survey/reported | WHO/UNICEF |
| 92 | 2008 | Survey/reported | WHO/UNICEF |
| 96 | 2007 | Survey/reported | WHO/UNICEF |
| 82 | 2006 | Survey/reported | WHO/UNICEF |
| 85 | 2005 | Survey/reported | WHO/UNICEF |
| 77 | 2004 | Survey/reported | WHO/UNICEF |
| 68 | 2003 | Survey/reported | WHO/UNICEF |
| 72 | 2002 | Survey/reported | WHO/UNICEF |
| 77 | 2001 | Survey/reported | WHO/UNICEF |
| 71 | 2000 | Survey/reported | WHO/UNICEF |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 0 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.99 (0.82 - 1.23) | 2019 | Modelled | IHME |
| 0.84 (0.68 - 1.01) | 2018 | Modelled | IHME |
| 0.77 (0.63 - 0.91) | 2017 | Modelled | IHME |
| 0.78 (0.66 - 0.91) | 2016 | Modelled | IHME |
| 0.79 (0.68 - 0.92) | 2015 | Modelled | IHME |
| 0.79 (0.68 - 0.91) | 2014 | Modelled | IHME |
| 0.78 (0.68 - 0.90) | 2013 | Modelled | IHME |
| 0.77 (0.67 - 0.88) | 2012 | Modelled | IHME |
| 0.76 (0.66 - 0.87) | 2011 | Modelled | IHME |
| 0.75 (0.66 - 0.86) | 2010 | Modelled | IHME |
| 0.74 (0.65 - 0.84) | 2009 | Modelled | IHME |
| 0.73 (0.64 - 0.82) | 2008 | Modelled | IHME |
| 0.71 (0.63 - 0.81) | 2007 | Modelled | IHME |
| 0.7 (0.61 - 0.80) | 2006 | Modelled | IHME |
| 0.69 (0.61 - 0.79) | 2005 | Modelled | IHME |
| 0.69 (0.60 - 0.79) | 2004 | Modelled | IHME |
| 0.69 (0.59 - 0.79) | 2003 | Modelled | IHME |
| 0.69 (0.59 - 0.80) | 2002 | Modelled | IHME |
| 0.68 (0.58 - 0.80) | 2001 | Modelled | IHME |
| 0.68 (0.58 - 0.80) | 2000 | Modelled | IHME |
| 0.69 (0.59 - 0.81) | 1999 | Modelled | IHME |
| 0.71 (0.60 - 0.83) | 1998 | Modelled | IHME |
| 0.73 (0.61 - 0.86) | 1997 | Modelled | IHME |
| 0.76 (0.63 - 0.90) | 1996 | Modelled | IHME |
| 0.78 (0.65 - 0.95) | 1995 | Modelled | IHME |
| 0.81 (0.67 - 0.99) | 1994 | Modelled | IHME |
| 0.85 (0.70 - 1.04) | 1993 | Modelled | IHME |
| 0.89 (0.73 - 1.09) | 1992 | Modelled | IHME |
| 0.93 (0.76 - 1.15) | 1991 | Modelled | IHME |
| 0.98 (0.79 - 1.21) | 1990 | Modelled | IHME |
Showing out of
Show more
Prevalence of anti-HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 1 | 2009 | Survey/reported | Zeynep F et al, 2008. |
| 0.3 | 2003 | Survey/reported | Ozsoy MF et al, 2003 |
| 1 (0.60 - 2.10) | 2014 | Modelled | Gower et al, 2014 |
Showing out of
Show more
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 44.9 (41.70 - 48.20) | 2015 | Modelled | Degenhardt L et al, 2017 |
HCV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 3.22 (2.35 - 4.29) | 2019 | Modelled | IHME |
| 3.16 (2.33 - 4.10) | 2018 | Modelled | IHME |
| 3.1 (2.33 - 4.04) | 2017 | Modelled | IHME |
| 2.96 (2.25 - 3.76) | 2016 | Modelled | IHME |
| 2.85 (2.20 - 3.53) | 2015 | Modelled | IHME |
| 2.84 (2.24 - 3.49) | 2014 | Modelled | IHME |
| 2.82 (2.23 - 3.48) | 2013 | Modelled | IHME |
| 2.8 (2.23 - 3.49) | 2012 | Modelled | IHME |
| 2.8 (2.24 - 3.52) | 2011 | Modelled | IHME |
| 2.77 (2.20 - 3.46) | 2010 | Modelled | IHME |
| 2.69 (2.10 - 3.38) | 2009 | Modelled | IHME |
| 2.57 (1.94 - 3.26) | 2008 | Modelled | IHME |
| 2.42 (1.83 - 3.09) | 2007 | Modelled | IHME |
| 2.32 (1.75 - 2.95) | 2006 | Modelled | IHME |
| 2.28 (1.73 - 2.91) | 2005 | Modelled | IHME |
| 2.32 (1.76 - 2.97) | 2004 | Modelled | IHME |
| 2.38 (1.81 - 2.99) | 2003 | Modelled | IHME |
| 2.49 (1.93 - 3.06) | 2002 | Modelled | IHME |
| 2.45 (1.91 - 3) | 2001 | Modelled | IHME |
| 2.44 (1.87 - 2.99) | 2000 | Modelled | IHME |
| 2.55 (1.93 - 3.18) | 1999 | Modelled | IHME |
| 2.62 (1.94 - 3.29) | 1998 | Modelled | IHME |
| 2.64 (1.97 - 3.33) | 1997 | Modelled | IHME |
| 2.62 (1.92 - 3.34) | 1996 | Modelled | IHME |
| 2.65 (1.93 - 3.39) | 1995 | Modelled | IHME |
| 2.67 (1.89 - 3.44) | 1994 | Modelled | IHME |
| 2.68 (1.89 - 3.49) | 1993 | Modelled | IHME |
| 2.71 (1.89 - 3.57) | 1992 | Modelled | IHME |
| 2.77 (1.88 - 3.65) | 1991 | Modelled | IHME |
| 2.83 (1.89 - 3.74) | 1990 | Modelled | IHME |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 2,624 (1,910 - 3,491) | 2019 | Modelled | IHME |
| 2,558 (1,891 - 3,326) | 2018 | Modelled | IHME |
| 2,501 (1,883 - 3,262) | 2017 | Modelled | IHME |
| 2,371 (1,804 - 3,012) | 2016 | Modelled | IHME |
| 2,258 (1,742 - 2,802) | 2015 | Modelled | IHME |
| 2,225 (1,756 - 2,739) | 2014 | Modelled | IHME |
| 2,181 (1,722 - 2,691) | 2013 | Modelled | IHME |
| 2,131 (1,700 - 2,656) | 2012 | Modelled | IHME |
| 2,114 (1,689 - 2,654) | 2011 | Modelled | IHME |
| 2,071 (1,644 - 2,587) | 2010 | Modelled | IHME |
| 2,003 (1,564 - 2,516) | 2009 | Modelled | IHME |
| 1,898 (1,438 - 2,413) | 2008 | Modelled | IHME |
| 1,777 (1,348 - 2,272) | 2007 | Modelled | IHME |
| 1,691 (1,277 - 2,151) | 2006 | Modelled | IHME |
| 1,651 (1,253 - 2,112) | 2005 | Modelled | IHME |
| 1,668 (1,267 - 2,139) | 2004 | Modelled | IHME |
| 1,701 (1,294 - 2,130) | 2003 | Modelled | IHME |
| 1,757 (1,364 - 2,162) | 2002 | Modelled | IHME |
| 1,713 (1,334 - 2,096) | 2001 | Modelled | IHME |
| 1,688 (1,293 - 2,070) | 2000 | Modelled | IHME |
| 1,750 (1,322 - 2,178) | 1999 | Modelled | IHME |
| 1,770 (1,314 - 2,228) | 1998 | Modelled | IHME |
| 1,763 (1,313 - 2,222) | 1997 | Modelled | IHME |
| 1,730 (1,265 - 2,202) | 1996 | Modelled | IHME |
| 1,725 (1,254 - 2,201) | 1995 | Modelled | IHME |
| 1,709 (1,209 - 2,201) | 1994 | Modelled | IHME |
| 1,686 (1,192 - 2,201) | 1993 | Modelled | IHME |
| 1,680 (1,172 - 2,215) | 1992 | Modelled | IHME |
| 1,688 (1,145 - 2,224) | 1991 | Modelled | IHME |
| 1,689 (1,127 - 2,238) | 1990 | Modelled | IHME |
| 2,492 | 2016 | Modelled | WHO |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 28 (21 - 35) | 2019 | Modelled | IHME |
| 28 (21 - 35) | 2018 | Modelled | IHME |
| 28 (21 - 35) | 2017 | Modelled | IHME |
| 28 (21 - 34) | 2016 | Modelled | IHME |
| 27 (20 - 34) | 2015 | Modelled | IHME |
| 27 (21 - 34) | 2014 | Modelled | IHME |
| 27 (21 - 34) | 2013 | Modelled | IHME |
| 27 (20 - 34) | 2012 | Modelled | IHME |
| 27 (20 - 33) | 2011 | Modelled | IHME |
| 26 (20 - 33) | 2010 | Modelled | IHME |
| 26 (19 - 33) | 2009 | Modelled | IHME |
| 26 (19 - 33) | 2008 | Modelled | IHME |
| 25 (19 - 31) | 2007 | Modelled | IHME |
| 24 (18 - 30) | 2006 | Modelled | IHME |
| 23 (17 - 30) | 2005 | Modelled | IHME |
| 23 (17 - 29) | 2004 | Modelled | IHME |
| 24 (17 - 30) | 2003 | Modelled | IHME |
| 24 (17 - 30) | 2002 | Modelled | IHME |
| 24 (17 - 31) | 2001 | Modelled | IHME |
| 24 (17 - 30) | 2000 | Modelled | IHME |
| 24 (17 - 30) | 1999 | Modelled | IHME |
| 24 (17 - 30) | 1998 | Modelled | IHME |
| 24 (17 - 31) | 1997 | Modelled | IHME |
| 24 (17 - 31) | 1996 | Modelled | IHME |
| 24 (17 - 31) | 1995 | Modelled | IHME |
| 24 (17 - 31) | 1994 | Modelled | IHME |
| 24 (17 - 31) | 1993 | Modelled | IHME |
| 24 (18 - 31) | 1992 | Modelled | IHME |
| 24 (17 - 31) | 1991 | Modelled | IHME |
| 24 (17 - 31) | 1990 | Modelled | IHME |
Showing out of
Show more
Number of needles/syringes per PWID per year
People who inject drugs (PWID)
Download| Value | Year | Type | Source |
|---|---|---|---|
| 300 (0 - 0) | 2016 | Survey/reported | Harm Reduction International, 2016 |
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
2003
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
HBV (HBsAg+)
2.43
(%)
2019
(2.31 - 2.56(%))
IHME
HCV (RNA/cAg+)
0.99
(%)
2019
(0.82 - 1.23(%))
IHME
Survey/surveillance
HBV (HBsAg+)
2.5
(%)
2009
Akcama FZ et al, 2009
HCV (anti-HCV)
1
(%)
2009
Zeynep F et al, 2008.
Hepatitis related deaths (national)
Modelled
HBV
3,530
2019
(2,645 - 4,618)
IHME
Survey/surveillance
No data available
HBV chart
Modelled
HCV
2,624
2019
(1,910 - 3,491)
IHME
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.17
(%)
2019, latest modelled
(0.14 - 0.20(%))
IHME
Prevalence PWID
HCV
44.90
(%)
2015, latest modelled
(41.70 - 48.20(%))
Degenhardt L et al, 2017
Birth dose vaccination coverage (national)
Survey/surveillance
HBV
99
(%)
2018
WHO/UNICEF
No. of syringes/PWID/year
Survey/surveillance
HCV
0
2016
(0 - 0)
Harm Reduction International, 2016
Eligible for HBV generic medicines
Eligible for HCV generic medicines
